Metastatic Castration-Resistant Prostate Cancer: Treatment Selection and Sequencing With Tanya Dorff, MD
Devi Seal
Expert Analysis
Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-re...
Veno-Occlusive Disease: An Interview with Phyllis McKiernan, APN, MSN, OCN® and Michelle N. Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON
Devi Seal
Expert Analysis
Veno-occlusive disease (VOD) is a potentially life-threatening complication of hematopoietic stem cell transplant. In patients with severe cases, the mortality rate has been estimated to be greater than 80%. In this exclusive interview, Phyllis McKiernan, APN, MSN, OCN and Michelle Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON spoke with i3 Health about challenges, patient education strategies, and best practices in nursing management of adult and pediatric patients with VOD.​
What do you consider "sorafenib failure?" Progression on radiological evaluation, clinical evaluation, or both?
Devi Seal
Expert Analysis
Thomas A. Abrams, MD: Clinical deterioration that is not related to obvious AEs of sorafenib has to be regarded as a progression or sorafenib failure, especially if there's corroborating evidence such as biochemical worsening, AFPs going up, worsening liver function, or ascites. Those could be used as a surrogate to progression. If radiological dat...

Copyright © 2022 Oncology Data Advisor. All rights reserved.